Rollx Vans
 
Research Updates

Research Updates

Blood-vessel narrowing implicated in exercise-related fatigue

Missing or reduced levels of an enzyme known as neuronal nitric oxide synthase (nNOS) at its normal location on muscle-fiber membranes prevents blood vessels that supply active muscles from relaxing normally, leading to exercise-associated fatigue, says a team of researchers from the University of Iowa in Iowa City, the University of Michigan in Ann Arbor, and the University of Washington School of Medicine in Seattle.

Erik Rader
Erik Rader, an MDA grantee, was part of a research group that found blood vessels don’t dilate properly when nNOS isn’t tethered to the muscle-fiber membrane.

The team, coordinated by longtime MDA grantee Kevin Campbell at the University of Iowa, published its findings online Oct. 26 in Nature. MDA supported Erik Rader at that institution for this work.

In normal skeletal muscle, nNOS is anchored to the membrane surrounding a muscle fiber via a cluster of proteins (see illustration). When stimulated by active muscle, nNOS makes a signaling molecule called nitric oxide, which causes a cascade of effects that leads to relaxation of blood vessels and an increase in blood flow to active muscles.

When the protein cluster in the muscle-fiber membrane is disrupted, as occurs in Duchenne muscular dystrophy (DMD) and type 2D limb-girdle muscular dystrophy (LGMD2D), nNOS loses its anchor to the membrane, affecting events downstream of the nitric oxide signaling pathway.

To probe the molecular basis of the exercise-induced fatigue common in people with neuromuscular diseases, the researchers conducted a series of experiments in which they assessed post-exercise activity in mice with and without properly anchored nNOS.

Muscle-Fiber Membrane Proteins
Muscle-Fiber Membrane Proteins with Utrophin Instead of Dystrophin

Study results ruled out cardiac dysfunction, inflammation, pain, muscle damage and lack of muscle force as causes of the exercise-related fatigue, and suggested instead that it was caused by a loss of membrane-localized nNOS.

The team found a similar deficit in nNOS at the muscle-cell membrane in tissue samples from human patients with a wide range of myopathies, suggesting a shared mechanism of fatigue.

The investigators next either blocked the nNOS signaling pathway or caused vasoconstriction (blood-vessel narrowing) with drugs. Mice treated this way, although healthy, experienced fatigue after mild exercise similar to that experienced by mice with muscular dystrophy or with deficient nNOS. This finding suggests that the absence of properly located nNOS leads to deficient signaling to blood vessels that feed active muscles, thus causing fatigue after only mild exercise.

In further studies, the investigators eliminated the exaggerated fatigue response when they treated mice deficient in nNOS with a phosphodiesterase inhibitor, a drug such as sildenafil (Viagra) that enhances the blood-vessel relaxation signal.

As indicated in another recent study performed by a research team that included MDA grantee Basil Petrof at McGill University in Montreal, the effect of Viagra on blood vessels extends to the coronary arteries. Those investigators found treatment with sildenafil significantly improved heart function in mice missing the dystrophin protein and showing a disease resembling DMD. (See Research Updates, September-October 2008.)  

Lab-engineered protein increased utrophin production in DMD mice

MDA-supported researchers at the Montreal Neurological Institute of McGill University substantially improved muscle health and resistance to mechanical stress in mice with a disease resembling human Duchenne muscular dystrophy (DMD) by increasing production and distribution of a protein known as utrophin.

The investigators, including MDA grantees George Karpati and Josephine Nalbantoglu, published their findings online Oct. 21 in the Journal of Biological Chemistry.

In their report, they describe how they designed a chemical switch they dubbed zinc-finger protein 51 (ZFP51) that activated utrophin genes, thereby causing muscle fibers to make more utrophin protein and expanding utrophin’s location from one small area to the whole fiber.

Utrophin is a protein similar in structure to dystrophin, the protein missing in boys with DMD and in DMD mice. Unlike dystrophin, the utrophin gene remains intact in DMD patients and dystrophin-deficient mice, and its protein product has a small protective effect when dystrophin is absent.

Josephine Nalbantoglu
Josephine Nalbantoglu at McGill University received MDA support for studies that used a lab-engineered protein to increase utrophin production.

However, utrophin is unable to effectively offset the absence of dystrophin, in part because its structure is slightly different, but mostly because there isn’t enough of it and it’s concentrated in only one place, at the junction of nerve and muscle fibers. In contrast, dystrophin is normally found bordering the entire muscle fiber, and it plays a role in stabilizing the fiber membrane. In addition, protein clusters constructed with utrophin don’t include nNOS. (See “Blood-vessel narrowing” and illustration.)

When dystrophin-deficient mice were given an injection of ZFP51 genes into one leg muscle and an injection without the ZFP51 gene (a “control”) into the corresponding muscle in the opposite leg, only the legs that received the ZFP51 genes showed benefit. The ZFP51-injected muscles functioned better and had less muscle-fiber destruction. They also showed restoration of a normal cluster of proteins at the muscle-fiber membrane and improved resistance to injury from muscle contractions.

The mice showed no obvious toxic effects from the treatment, although the researchers acknowledge that compounds like ZFP51 would have to undergo extensive testing to ensure they didn’t activate genes other than those targeted.

They would also have to ensure that the ZFP genes and the transporters used to deliver them to muscle would not elicit an unwanted immune response from recipients.

“The ZFP is a small protein, and it will probably not be an immune problem,” Karpati said. He also noted that an improved ZFP gene delivery vehicle (“vector”) they plan to use in future experiments “would make the immunogenicity [ability to cause an immune response] of the vector negligible.”

Nalbantoglu, who coordinated the project, and colleagues, say in their report that their studies “highlight the considerable therapeutic potential of artificial ZFPs for treating DMD.”

Asked whether utrophin-containing protein clusters would be deficient in nNOS, she commented that the effects on exercise-induced fatigue occur downstream of nNOS signaling and that the lack of dystrophin could likely be bypassed.

Signal-blocking compound markedly improved heart function in EDMD mice

Treatment with a compound that blocks a signaling pathway in the hearts of mice with a disease resembling human Emery-Dreifuss muscular dystrophy (EDMD) resulted in markedly improved cardiac function compared to that seen in untreated EDMD mice, researchers at Columbia University in New York and the Institute of Myology in Paris found.

Howard Worman, a professor and MDA grantee at Columbia, coordinated a group of investigators who published their results online Oct. 16 in Human Molecular Genetics.

Previous work by Worman and colleagues has shown that mutations (flaws) in the lamin A/C gene, which cause EDMD in mice and in humans, lead to abnormal activation of a signaling pathway in the heart called ERK.

In this recent set of experiments, the investigators gave a compound called PD98059, which blocks the ERK signaling pathway, to mice with a lamin A/C gene mutation, while giving other mice with this mutation an inactive substance (placebo) or no treatment at all. They also studied heart function in normal mice.

After eight weeks, the mice that had received injections of PD98059 showed values similar to the normal mice on four measures of heart function. The untreated and the placebo-treated mice, however, showed markedly different values from the normal mice on two of these measures.

In addition to the functional differences, the researchers noted that the nuclei of cardiac muscle cells differed in shape in the different groups of mice.

The normal and PD98059-treated EDMD mice had cardiac muscle cells with well-rounded, oval nuclei, whereas the nuclei in these cells in untreated or placebo-treated EDMD mice had an abnormal, elongated shape.

The lamin A and lamin C proteins are made from the lamin A/C gene’s instructions, and they form part of the envelope that surrounds each cell nucleus (the “nuclear envelope”). Therefore, these nuclear shape differences could reflect lamin abnormalities.

Nucleus of a Muscle Cell
EDMD can be caused by abnormalities of one of the lamins or of emerin, located in or near the inner membrane of the nuclear envelope. Lamin abnormalities, and possibly emerin abnormalities, can trigger abnormal activation of a heart-damaging pathway.

EDMD caused by lamin A/C gene mutations is one of two types of EDMD, the other type being caused by mutations in the gene for emerin, another nuclear-envelope protein. The researchers say their findings in a lamin-related EDMD mouse model also may be relevant in emerin-related EDMD, but they have not yet performed any experiments to demonstrate this.

They say their results support the hypothesis that ERK pathway activation caused by lamin abnormalities is an underlying cause of heart-muscle degeneration (cardiomyopathy) in EDMD and that their new results provide evidence that blocking ERK could prevent or delay the onset of heart failure in this disease.

They also note that medications that block ERK have been safely administered to people with cancer.

Sarcospan protein unexpectedly saves MD-affected muscle fibers

A small protein known as sarcospan appears to have much more potential as a treatment for Duchenne muscular dystrophy (DMD) and perhaps other types of muscular dystrophy (MD) than previously believed, say researchers at the University of California-Los Angeles.

Rachelle Crosbie, who has received intermittent MDA funding since the late 1990s, and colleagues, published the sarcospan findings in the Nov. 3 issue of the Journal of Cell Biology. (Crosbie received support from the National Institutes of Health for this project.)

Sarcospan is part of the cluster of proteins at the muscle-fiber membrane that also includes dystrophin, the protein missing in DMD, and the sarcoglycans, which are missing in some types of limb-girdle muscular dystrophy (LGMD) (see illustration).

Normally, these clusters, closely spaced at intervals around the periphery of muscle fibers, protect the fibers from injury related to mechanical stress. A loss or deficiency of any of the elements of the cluster, such as occurs in DMD and some LGMDs, can destabilize the entire structure, leaving the muscle fiber vulnerable to damage.

Early in life, utrophin, which is very similar to dystrophin, is in these clusters, but it’s replaced by dystrophin as the muscles mature.

Several studies have shown dystrophin-deficient mice with extra utrophin do better than those without it, and various methods to increase utrophin production are being explored as strategies for DMD treatment. (See “Lab-engineered protein”.) Crosbie and colleagues decided instead to explore raising sarcospan levels in muscle fibers.

Unexpectedly, the presence of extra sarcospan (created by giving dystrophin-deficient mice several sarcospan genes) led to the appearance of utrophin-containing protein clusters all around muscle fibers, not just at the specialized nerve-muscle meeting places where they’re normally found. Moreover, the sarcospan-enriched muscles looked healthier than those of the untreated dystrophin-deficient mice, with fewer degenerating fibers.

The investigators say they don’t believe sarcospan increased utrophin production. Instead, they think it stabilized utrophin and allowed it to expand its role and its territory and to substitute for dystrophin.

They note the small size of the sarcospan gene compared to genes for dystrophin or utrophin would make it relatively easy to administer as a gene therapy, and that its widespread presence in muscle tissue would make an unwanted immune response to it unlikely.

AAV9 achieves body-wide gene delivery

Researchers at the University of Missouri, the University of North Carolina and Auburn (Ala.) University have found that a vector (a delivery vehicle for transferring genetic material) based on adeno-associated virus 9 (AAV9) reached all the skeletal muscles of young dogs after a single intravenous injection.

The finding is considered significant, because treating muscle disease with gene therapy is likely to require that the therapy reach all muscles after systemic administration.

MDA funded Dongsheng Duan at the University of Missouri, Joe Kornegay at the University of North Carolina, and Bruce Smith at Auburn University for this work.

In a paper published online Sep. 30 in Molecular Therapy, Duan and colleagues describe experiments designed to determine the effectiveness of local and systemic injection of AAV9 as a potential gene therapy delivery method for a host of muscle diseases.

To test the AAV9 delivery system, they first inserted a gene that carries instructions for the alkaline phosphatase (AP) protein into AAV9 shells and injected it directly into muscle. 

Dongsheng Duan
MDA grantee Dongsheng Duan at the University of Missouri has explored AAV9 as a gene-therapy delivery vehicle.

Genes injected directly into muscle provoked an unwanted immune reaction when administered to mature animals. However, they were accepted well if given very early in life.

Researchers next tested whether body-wide gene delivery could be achieved by delivering a high dose or low dose of gene-carrying AAV9 through a vein in each of four animals.

Examinations at two and six weeks after gene transfer showed a dose-dependent response; those that received low-dose AAV9 had fewer AP-positive fibers than the ones that received the high dose.

Six months after the intravenous gene transfer, nearly every skeletal muscle showed efficient AP expression with greater than 50 percent of muscle fibers AP-positive. However, the intravenously administered genes failed to enter the heart muscle, which is affected in many muscle diseases. (Earlier experiments by Duan and colleagues, conducted in mice, found AAV9 targeted the heart.)

“We’re currently working to further improve the technique to achieve not only skeletal muscle but also heart-muscle transduction [entry],” Duan said. “Many muscular dystrophy patients suffer from heart disease.  A technique that can reach both skeletal muscle and the heart will be more appealing.” 

The investigators note the importance of age at the time of gene delivery and suggest the immune response hurdle may be cleared in newborns, as their immature immune systems may not mount a vigorous response to therapy.

Two gene therapy trials, one in boys with Duchenne muscular dystrophy and another in people with alpha-sarcoglycan-deficient limb-girdle muscular dystrophy (LGMD2D), have received MDA support and are under way. At the same time, however, the search for better delivery vehicles and ways to circumvent an unwanted immune response continues.

Neural stem cells aid survival and function in SMA mice

Mice with a disease resembling human spinal muscular atrophy (SMA) that were treated with specialized stem cells lived 39 percent longer and showed better neuromuscular function than did untreated mice, lending support for development of this type of therapy for SMA.

Investigators coordinated by Giacomo Comi at the University of Milan (Italy), who published their findings in the October issue of the Journal of Clinical Investigation, isolated neural stem cells, which can become motor neurons under certain conditions, from the spinal cords of mouse embryos not affected by SMA.

After exposing these cells to growth-promoting substances and other chemicals and allowing them to multiply in the laboratory, the researchers injected them into the spinal fluid of 1-day-old SMA mice.

The donor cells migrated into the spinal cords of the SMA mice, where they generated cells that appeared to be motor neurons (the muscle-controlling nerve cells that die in SMA). The donor cells may also have aided existing motor neurons in their struggle to survive.

“It is conceivable,” the authors note, “that in the future, stem cell transplantation could be combined with other molecular and pharmacologic approaches to achieve an effective recovery.”

Missing link identified at nerve-muscle junction

MDA grantee Lin Mei recently coordinated a team of scientists who identified a previously missing link necessary to the mechanism that allows signals to pass from nerve to muscle cells. Without these signals, muscles cannot contract.

The protein, known as LRP4, is now known to connect two other proteins, agrin and MuSK, at the neuromuscular junction, the meeting place of nerve and muscle fibers.

“LRP4 is both necessary and sufficient to bind [stick] to agrin and activate MuSK signaling,” note Bin Zhang at the Medical College of Georgia, and colleagues, who published their findings in the Oct. 23 issue of the journal Neuron. The MuSK protein tells the part of the muscle fiber that receives nerve signals to form and maintain clusters of special landing pads for these signals.

Mei also notes that another research group, led by Steven Burden at New York University in Manhattan, independently made the same discovery and published it Oct. 17 in the journal Cell.

Disruptions of signal transmission at the neuromuscular junction can be caused by a mistaken immune-system attack on any of several of its components or by genetic abnormalities in these components.

Immune-system destruction of the signaling protein MuSK or the landing pads, which are called acetylcholine receptors, causes myasthenia gravis (MG), a disease involving interrupted signals that lead to fluctuating weakness.

The investigators note that their results “suggest that LRP4 may be a potential culprit” as well in some diseases of the neuromuscular junction and could become a new target for therapies.

DNA test now available based on MDA grantee’s ID of gene for CNM

The University of Chicago Genetics Services Laboratory now offers a DNA test to identify flaws in the dynamin 2 (DNM2) gene that can cause a form of centronuclear myopathy (CNM).

In 2005, MDA grantee Alan Beggs at Children’s Hospital Boston and a multinational team of researchers identified flaws in the DNM2 gene as a cause of CNM. The findings led to this new genetic test.

The lab requires a blood sample, which can be obtained locally. The cost is $2,025, which may or may not be partially covered by insurance. You can arrange for a CNM genetic test through your MDA clinic physician or genetic counselor, who should contact the University of Chicago Genetic Services Laboratories at (773) 834-0555 or ucgslabs@genetics.uchicago.edu. The Web site is http://genes.uchicago.edu/aboutlab.html.

CLINICAL TRIALS AND STUDIES

Genzyme continues studying Myozyme in Pompe disease
The biopharmaceutical company Genzyme, based in Cambridge, Mass., continues to conduct several studies to refine the usage of its drug, Myozyme, for the treatment of Pompe disease (acid maltase deficiency). (For more about Myozyme, see “Rescued Lives”.) The studies include:

  • a five-participant trial to investigate the possible benefit of giving two immunosuppressant drugs prior to Myozyme infusions in patients with infantile-onset Pompe disease who are not making any acid maltase;
  • a 30-participant study of long-term growth and development in infants less than 1 year old who are on Myozyme;
  • a 14-person study of alternative dosing regimens of Myozyme in patients at least 6 months old who have not had an optimal response to the standard dosing schedule; and
  • a nine-person study of Pompe patients at least 6 months old to see whether either of two types of immunosuppressive regimens in combination with Myozyme is safe or beneficial.
For all studies, contact Genzyme Medical Information at (800) 745-4447 or (617) 252-7832 or medinfo@genzyme.com; or see www.mda.org/research/ctrials.aspx.

Amicus is studying pharmacological chaperone in Pompe disease

Cranbury, N.J., biopharmaceutical company Amicus Therapeutics is testing a molecule it calls AT2220 in adults with Pompe disease (acid maltase deficiency) at some 20 trial sites in the United States, Canada and Europe.

Participants cannot have received enzyme replacement therapy for at least three months prior to study entry and must agree not to receive it during the study; must not require noninvasive ventilatory support more than eight hours a day while awake; and must meet other study criteria.

AT2220 is a pharmacological chaperone, meaning it helps proteins fold into their proper shape. In Pompe disease, it’s hoped the chaperone will stabilize and improve the effectiveness of abnormal acid maltase protein (enzyme) molecules made by patients. For information, call Amicus at (609) 662-2000, or send e-mail to clinicaltrials@amicustherapeutics.com.

Diaminopyridine under study in Lambert-Eaton syndrome

Adults 18 or older with Lambert-Eaton myasthenic syndrome (LEMS), a disorder in which weakness results from deficient signaling from nerve to muscle fibers, can participate in a study of 3,4-diaminopyridine, a drug that has been shown to be effective in treating this condition but is not approved by the U.S. Food and Drug Administration. Contact Janelle Butters at (916) 734-6276 or Janelle.butters@ucdmc.ucdavis.edu.

Acceleron testing compound to slow muscle wasting

A compound known as ACE031, developed by Acceleron Pharma of Cambridge, Mass., to block biochemical signaling involved in muscle wasting, is now being tested in healthy volunteers in Canada. The compound has shown promise in animal models of neuromuscular disease, as well as models of age-related muscle loss and other muscle-wasting conditions. This phase 1 trial is to evaluate the drug’s safety and its distribution and metabolism in the body.

Exon skipping drug may get EU orphan drug status

AVI BioPharma, a drug development company in Corvallis, Ore., announced Oct. 14 that AVI4658, its exon skipping compound for Duchenne muscular dystrophy (DMD), has been recommended for orphan drug status in the European Union. This status gives financial incentives to companies that develop therapies for rare diseases, including exclusive marketing rights for up to 10 years.

At the same time, the company announced that the United Kingdom’s Gene Therapy Advisory Committee had granted provisional approval for a planned clinical trial for systemic delivery of AVI4658 to treat DMD.

The compound is now being tested in a clinical trial in a small number of boys with DMD in the United Kingdom, as a local injection into a foot muscle.

Exon skipping compounds, also known as “antisense,” target specific mutations (errors) in genes. They’re designed to cause cellular mechanisms that “read” genetic instructions to skip, or ignore, an error-containing section of a gene so that a functional protein can be made.

AVI4658 specifically targets exon (section) 51 of the gene for the dystrophin protein. Mutations in this gene can lead to DMD or Becker muscular dystrophy.

Compounds known as antisense can cause cells to skip (ignore) a flawed exon (section) of a gene, splice together the surrounding sections, and produce a nearly normal version of a protein, such as dystrophin.
Compounds known as antisense can cause cells to skip (ignore) a flawed exon (section) of a gene, splice together the surrounding sections, and produce a nearly normal version of a protein, such as dystrophin.

Study of thymectomy in people with MG broadens criteria

A 200-participant, multicenter study to determine whether removal of the thymus gland (thymectomy) in people with myasthenia gravis (MG) allows for a reduced dosage or withdrawal of the steroid drug prednisone remains open. The study has broadened participation criteria to include people whose MG started within the last five years and who are between 18 and 65 years old, if they meet other study criteria. Contact Greg Minisman at the University of Alabama-Birmingham at (205) 934-4905.

Researchers are seeking metabolic ‘signature’ of mitochondrial diseases

Investigators at Children’s Hospital of Philadelphia are seeking people with a definite biochemical and/or genetic diagnosis of a mitochondrial disease for a study to identify the changes in metabolism caused by this type of disorder. Being able to recognize a pattern of changes (metabolic “signature”) could aid in diagnosis and treatment. The study will primarily use previously collected muscle, skin and blood samples, although new blood or skin specimens may be requested. Contact Emily Place at Children’s Hospital of Philadelphia at (267) 426-9650 or placee@email.chop.edu.

Study of exercise in mitochondrial disease under way at UT Southwestern

A 50-person, two-year study to determine whether exercise benefits adults with mitochondrial myopathies is under way at the University of Texas Southwestern Medical Center in Dallas. Ronald Haller, who has had MDA support for research in this area, is the principal investigator. Participants must be 18 to 60 years old, have a diagnosis of mitochondrial myopathy based on DNA testing, be free of heart disease and high blood pressure, and meet other study criteria. Contact Marta Newby at (214) 345-4655 or martanewby@texashealth.org.

Graduate student seeks parents’ views of genetic counseling for DMD, BMD

A questionnaire-based study to assess parents’ knowledge of Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) and seek their views of the genetic counselng process is being conducted by Boston University genetic counseling student Molly McGinniss. An online questionnaire for parents of children with DMD or BMD is available at http://people.bu.edu/mollymcg/molly.html. For a paper version, contact Molly McGinniss at (858) 414-1209 or mollymcg@bu.edu.

SMA registry now allows Web-based participation

An international patient registry that collects anonymous data on children and adults with spinal muscular atrophy (SMA) for research purposes has expanded its format so that participants now can submit data online. The new Web site is http://smaregistry.iu.edu.

Those who would rather have paper forms mailed to them can contact Connie Garland at IU at (317) 274-5745 or cjgar-lan@iupui.edu.

This project is supported by the Patient Advisory Group of the International Coordinating Committee for SMA Clinical Trials, which includes Families of SMA, Fight SMA, MDA, the SMA Foundation and other SMA advocacy groups.

RESEARCH ADMINISTRATION

Updated MD-CARE Act is now law

The Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education (MD-CARE) Amendments of 2008 received final Congressional approval on Sept. 27 and were signed into law by President Bush Oct. 8.

The legislation reauthorizes and updates the MD-CARE Act of 2001 and will escalate research and development of treatments for several forms of muscular dystrophy.

The original Act required that the National Institutes of Health (NIH) designate muscular dystrophy research “centers of excellence” to work independently and collaboratively. MDA aided creation of these centers by contributing $1.5 million to each of the first three.

The original Act also mandated creation of what is now the Muscular Dystrophy Coordinating Committee to expand research efforts; established an epidemiological data collection system under the Centers for Disease Control and Prevention; and piloted a national care considerations project for Duchenne muscular dystrophy and Becker muscular dystrophy.

The amendments include several new provisions, such as expanding the epidemiological data collection to include health outcomes and reflect patients’ changing conditions over time; the development and broad distribution of care considerations in muscular dystrophy; and the “fast-tracking” of research findings into therapies.

Boston Biomedical becomes Wellstone MD center

Louis Kunkel
Louis Kunkel, who chairs MDA’s Scientific Advisory Committee, has been named co-director of the new Muscular Dystrophy Cooperative Research Center at Boston Biomedical Research Institute.

Boston Biomedical Research Institute (BBRI) in Watertown, Mass., was awarded $9 million in September from the U.S. National Institutes of Health (NIH) to become a Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center.

Ronald Cohn
Ronald Cohn, an MDA grantee at Johns Hopkins University, received a 2008 Director’s New Innovator Award from the U.S. National Institutes of Health.

Louis Kunkel, professor of genetics and pediatrics at Harvard Medical School and chairman of MDA’s Scientific Advisory Committee, was named co-director of the new center, with Charles Emerson Jr., senior scientist and director at BBRI.

Kunkel, a longtime MDA adviser who has received several MDA research grants, was on the MDA-funded scientific team at Harvard Medical School and Children’s Hospital in Boston that first identified the gene for Duchenne muscular dystrophy in 1986.

The BBRI center will focus on facioscapulohumeral muscular dystrophy (FSHD) research.

MDA grantee Ronald Cohn receives award

Ronald Cohn, an MDA-supported researcher at the McKusick-Nathans Institute of Genetic Medicine at Johns Hopkins University in Baltimore, received a 2008 Director’s New Innovator Award from the U.S. National Institutes of Health (NIH).

Cohn, an assistant professor of pediatrics and neurology, is studying the biology of muscle regeneration as it relates to various inherited and acquired muscle diseases. His MDA-funded research is focused on whether blocking a protein called TGF-beta can improve muscle health in muscular dystrophies.

The NIH Director’s New Innovator Award was created in 2007 to support a small number of new investigators whose research the Institutes judge is highly innovative and has the potential to produce a major impact on biomedical or behavioral research.


Error processing SSI file
Step It